Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease

References

• Japanese Respiratory SocietyJapanese Respiratory Society COPD Guideline ver. 4Tokyo, JapanTokyo Incorporated Association, JRS2013 Japanese
   Google Scholar
• BetsuyakuTKatoMFujimotoKA study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011Int J Chron Obstruct Pulmon Dis2013845345924124358
   PubMed Web of Science ®Google Scholar
• IchinoseMAizawaHIshizakaAChronic obstructive pulmonary disease (COPD) burden in Japan – confronting COPD Japan surveyNihon Kokyuki Gakkai Zasshi20074512927935 Japanese18186237
   PubMedGoogle Scholar
• NakanoYMishimaMNagaiAYoshimotoDUndiagnosed COPD in Japanese patients, aged over 40 with history of smoking and repeated chest infections, consulting in primary careJapan Med Assoc J201314210931098 Japanese
   Google Scholar
• FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology20049445846515612956
   PubMed Web of Science ®Google Scholar
• AgustiAGNCOPD, a multicomponent disease: implications for managementRespir Med200599667068215878483
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseGlobal Initiative for Chronic Obstructive Lung Disease Available from: http://www.goldcopd.com/uploads/users/files/GOLD_Report_2014_Oct30.pdfAccessed December 15, 2014
   Google Scholar
• FergusonGTAnzuetoAFeiREmmettAKnobilKKalbergCEffect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbationsRespir Med200810281099110818614347
   PubMed Web of Science ®Google Scholar
• IchinoseMMishimaMMashikoTNagaiAClinical study to evaluate the effects of changing from salmeterol to salmeterol/fluticasone propionate combination (SFC) in patients with COPDKokyu2008271110911100 Japanese
   Google Scholar
• BarnesNCQiuYSPavordIDSCO30005 Study GroupAntiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung diseaseAm J Respir Crit Care Med2006173773674316424444
   PubMed Web of Science ®Google Scholar
• BourbeauJChristodoulopoulosPMaltaisFYamauchiYOlivensteinRHamidQEffect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trialThorax2007621193894317557771
   PubMed Web of Science ®Google Scholar
• SinDDManSFPMarciniukDDABC (Advair, Biomarkers in COPD) InvestigatorsThe effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2008177111207121418310480
   PubMed Web of Science ®Google Scholar
• YawnBPRaphiouIHurleyJSDalalAAThe role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPDInt J Chron Obstruct Pulmon Dis2010516517820631816
   PubMedGoogle Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• Dal NegroRWPomariCTognellaSMichelettoCSalmeterol and fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophyllinePulm Pharmacol Ther200316424124612850128
   PubMed Web of Science ®Google Scholar
• AnzuetoAFergusonGTFeldmanGEffect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomesCOPD20096532032919863361
   PubMedGoogle Scholar
• MacNeeWSystemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary diseaseAnn Med201345329130023110517
   PubMed Web of Science ®Google Scholar
• DickensJAMillerBEEdwardsLDSilvermanEKLomasDATal-SingerRfor the Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study Investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohortRespir Res20111214622054035
   PubMed Web of Science ®Google Scholar
• RöpckeSHolzOLauerGRepeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputumPLoS One2012710e4620723056262
   PubMed Web of Science ®Google Scholar
• BizetoLMazzoliniABRibeiroMStelmachRCukierANunesMPInterrelationship between serum and sputum inflammatory mediators in chronic obstructive pulmonary diseaseBraz J Med Biol Res200841319319818327434
   PubMed Web of Science ®Google Scholar
• SinghDEdwardsLTal-SingerRRennardSSputum neutrophils as a biomarker in COPD: findings from the ECLIPSE studyRespir Res2010117720550701
   PubMed Web of Science ®Google Scholar
• PaggiaroPLChanezPHolzOSputum inductionEur Respir J Suppl2002373s8s12361361
   PubMedGoogle Scholar
• VestboJAndersonWCoxsonHOECLIPSE InvestigatorsEvaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)Eur Respir J200831486987318216052
   PubMed Web of Science ®Google Scholar
• van ElterenPHOn the combination of independent two-sample tests of WilcoxonB Int Statist Inst196037351361
   Google Scholar
• HendersonARThe bootstrap: a technique for data-driven statistics. Using computer-intensive analyses to explore experimental dataClin Chim Acta20053591–212615936746
   PubMed Web of Science ®Google Scholar
• StănescuDSannaAVeriterCAirways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophilsThorax19965132672718779129
   PubMed Web of Science ®Google Scholar
• LinFNguyenCMWangSJSaadiWGrossSPJeonNLEffective neutrophil chemotaxis is strongly influenced by mean IL-8 concentrationBiochem Biophys Res Commun2004319257658115178445
   PubMed Web of Science ®Google Scholar
• SohaniZNStrinichTXWatsonBReproducibility of sputum differential cell counts is not affected by squamous epithelial cellsJ Asthma201148995295622014007
   PubMed Web of Science ®Google Scholar
• TsoumakidouMTzanakisNSiafakasNMInduced sputum in the investigation of airway inflammation of COPDRespir Med200397886387112924512
   PubMed Web of Science ®Google Scholar
• JenRRennardSISinDDEffects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysisInt J Chron Obstruct Pulmon Dis2012758759523055709
   PubMed Web of Science ®Google Scholar
• MalerbaMRicciardoloFRadaeliANeutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjectsThorax200661212913316284217
   PubMed Web of Science ®Google Scholar
• KulkarniNCookeMSGriggJNeutrophils in induced sputum from healthy children: role of interleukin-8 and oxidative stressRespir Med2007101102108211217618102
   PubMed Web of Science ®Google Scholar
• IshikawaNHattoriNKohnoNKobayashiAHayamizuTJohnsonMAirway inflammation in Japanese COPD patients compared with smoking and nonsmoking controlsInt J Chron Obstruct Pulmon Dis20151018519225670894
   PubMed Web of Science ®Google Scholar
• BarnesNReducing inflammation in COPD: the evidence buildsThorax2007621192792817965073
   PubMed Web of Science ®Google Scholar
• LazarusSCChinchilliVMRollingsNJNational Heart Lung and Blood Institute’s Asthma Clinical Research NetworkSmoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthmaAm J Respir Crit Care Med2007175878379017204725
   PubMed Web of Science ®Google Scholar